Relapsed or Refractory Lymphomas; Advanced Solid Tumor
—
Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.
Status note Phase 2 Harmonic trial in never-smoking advanced NSCLC (with chemotherapy; IND under an existing application). After a May 2026 Type C FDA meeting, future enrollment focuses on EGFR exon 21 L858R-mutant patients.
LP-184
Phase 1 · Active
Aliases STAR-001
Target DNA
Partnerships Starlight Therapeutics (wholly owned subsidiary) developing LP-184 in CNS/brain-cancer indications; company refers to the molecule as STAR-001 in CNS indications
Status note Phase 1a enrollment completed; company advancing/optimizing development plans for multiple future LP-184 clinical studies.
LP-284
Phase 1 · Active
Target DNA
Indications
Hematological cancers(Phase 1)
Status note Stereoisomer (enantiomer) of LP-184; in a Phase 1A trial, targeting hematological cancers distinct from LP-184 indications.
LP-100
Stage not disclosed · Active
Status note Company says LP-100 has potential for future development in combination with PARP inhibitors (PARPi). The 10-Q notes LP-100 (like LP-300) showed promise in patient subgroups but failed a prior pivotal Phase 3 trial on overall results; it does not state discontinuation.
Per-asset detail extracted from the 10-Q filed 2026-08-14. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
Relapsed or Refractory Lymphomas; Advanced Solid Tumor
—
Sponsor-matched active trials from ClinicalTrials.gov (3 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.